GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (NAS:MDGL) » Definitions » Market Cap

Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Market Cap

: $4,446.39 Mil (As of Today)
View and export this data going back to 2007. Start your Free Trial

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Madrigal Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $231.38. Madrigal Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 19.88 Mil. Therefore, Madrigal Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $4,598.77 Mil.

Madrigal Pharmaceuticals's quarterly market cap declined from Jun. 2023 ($4,264.03 Mil) to Sep. 2023 ($2,700.89 Mil) but then increased from Sep. 2023 ($2,700.89 Mil) to Dec. 2023 ($4,598.77 Mil).

Madrigal Pharmaceuticals's annual market cap increased from Dec. 2021 ($1,449.34 Mil) to Dec. 2022 ($5,254.25 Mil) but then declined from Dec. 2022 ($5,254.25 Mil) to Dec. 2023 ($4,598.77 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Madrigal Pharmaceuticals's Enterprise Value for Today is $4,151.13 Mil.


Madrigal Pharmaceuticals Market Cap Historical Data

The historical data trend for Madrigal Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,405.75 1,724.05 1,449.34 5,254.25 4,598.77

Madrigal Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,254.25 4,429.26 4,264.03 2,700.89 4,598.77

Competitive Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals Market Cap Distribution

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Market Cap falls into.



Madrigal Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Madrigal Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$231.38*19.8754
=$4,598.77

Madrigal Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$231.38*19.8754
=$4,598.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Madrigal Pharmaceuticals  (NAS:MDGL) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Madrigal Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Executives
Robert E. Waltermire officer: Senior VP, Chief Pharma Dev. FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN PA 19428
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian Joseph Lynch officer: SVP and General Counsel 480 MORRIS ROAD, BLUE BELL PA 19422
William John Sibold director, officer: President and CEO C/O MADRIGAL PHARMACEUTICALS, INC., FOUR, TOWER BRIDGE, 200 BARR HARBOR DR STE 200, WEST CONSHOHOCKEN PA 19428
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Remy Sukhija officer: SVP and Chief Comm'l Officer 48 PHEASANT HILL ROAD, PRINCETON NJ 08540
Alex G. Howarth officer: Chief Financial Officer C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Fred B Craves director, 10 percent owner 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111